NDAORALTABLET
Approved
Dec 2017
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
3/8 — Basic
Drug data last refreshed 9h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SEGLUROMET is a fixed-dose oral combination of ertugliflozin (an SGLT2 inhibitor) and metformin hydrochloride (a biguanide), approved in December 2017 for type 2 diabetes. It combines two complementary mechanisms: metformin reduces hepatic glucose production and improves insulin sensitivity, while ertugliflozin increases urinary glucose excretion. This dual-action approach provides enhanced glycemic control in a single tablet.
$0.001BPart D
Peak5.4 years to LOEProduct is in mature peak stage with modest Medicare Part D utilization (2,394 claims in 2023), suggesting stable but limited commercial momentum and a smaller, focused brand team.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on SEGLUROMET offers limited career growth as a mature peak-stage product with zero linked job openings and modest commercial metrics. However, roles support core competencies in lifecycle management, competitive positioning in a crowded therapeutic area, and strategic planning for patent cliff preparation.
Brand ManagerSenior Medical Science Liaison
Worked on SEGLUROMET at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.